Last C$1.21 CAD
Change Today -0.15 / -11.03%
Volume 199.8K
IM On Other Exchanges
As of 3:59 PM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

imris inc (IM) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/4/14 - C$2.90
52 Week Low
12/16/14 - C$0.22
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for IMRIS INC (IM)

Related News

No related news articles were found.

imris inc (IM) Related Businessweek News

No Related Businessweek News Found

imris inc (IM) Details

IMRIS Inc. designs, manufactures, and sells image-guided therapy solutions that enable surgeons to obtain information and make decisions during the course of procedures. The company offers VISIUS Surgical Theatres, which deliver detailed visual information to clinicians during the course of various traditional surgical procedures that is used for various surgical applications, such as neurological, cardiovascular, cerebrovascular, interventional, and spine. The company’s products in development include magnetic resonance (MR) guided radiation therapy systems for use in MR imaging during radiotherapy treatments for cancer; and image guided surgical robotic systems for use in neurosurgical procedures. The company serves hospitals worldwide. IMRIS Inc. is based in Winnipeg, Canada.

137 Employees
Last Reported Date: 03/4/14

imris inc (IM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $421.0K
Total Annual Compensation: $253.8K
Executive Vice President of Operations
Total Annual Compensation: $250.0K
Chief Technology Officer and Executive Vice P...
Total Annual Compensation: $276.7K
Executive Vice President of Global Customer S...
Total Annual Compensation: $225.7K
Compensation as of Fiscal Year 2013.

imris inc (IM) Key Developments

IMRIS Regains Compliance With NASDAQ Listing Requirements

IMRIS Inc. announced that it has regained compliance with listing requirements of the NASDAQ Global Market. As previously reported, the Company received a letter, dated August 25, 2014, from the NASDAQ Stock Market LLC (NASDAQ) stating that for the previous 30 consecutive business days the bid price of the Company's common stock closed below the minimum $1.00 per share required for continued listing under NASDAQ Listing Rule 5450(a)(1). On February 13, 2015, the Company received a letter from NASDAQ stating that since the closing bid price of the Company's common stock had been greater than $1.00 for the last 10 consecutive business days, from January 30 to February 12, they determined that IMRIS was in compliance with Listing Rule 5450(a)(1) and that this matter was now closed.

IMRIS, Inc. Completes SYMBIS Surgical System Human Factors Study

IMRIS, Inc. announced that the company has successfully completed the human factors study for the SYMBIS Surgical System - the comprehensive validation used to support the product's 510(k) submission to the U.S. Food and Drug Administration (FDA) on November 26, 2014. Human factors is the science of understanding how humans interact physically and psychologically with a device. For example, in aviation, an engineer can develop an instrument; however, if the engineer fails to account for how a pilot uses this instrument in the cockpit, then user errors may result even if the instrument did its job. Over the past eight years, the FDA has been actively working with companies to apply the science of human factors to medical device development.

Boca Raton Regional Hospital Selects IMRIS Inc.'s Neurosurgical Suite

IMRIS Inc. has announced that Boca Raton Regional Hospital neurosurgeons have completed initial procedures to launch their use of the VISIUS Surgical Theatre with intraoperative MRI, or iMRI, within the new Marcus Neuroscience Institute. The VISIUS iCT suite which is expected to open in early November has three rooms with two for surgery and a storage bay in between the rooms. The 64-slice scanner will provide the higher quality computed tomography images available during surgery with low radiation exposure for the patient and surgical team.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IM:CN C$1.21 CAD -0.15

IM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
General Electric Co $26.11 USD +0.12
Koninklijke Philips NV €26.64 EUR -0.135
Medtronic PLC $78.83 USD +1.24
Siemens AG €98.62 EUR -0.80
View Industry Companies

Industry Analysis


Industry Average

Valuation IM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.9x
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMRIS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at